The primary aim of this trial is to establish the maximum tolerated dose (MTD) and the
recommended phase II dose (RP2D) of LDE225 given in combination with standard doses of
paclitaxel in patients with advanced solid tumors. In addition, the preliminary anti-tumor
activity of this combination will be assessed, in particular in ovarian cancer.